Skip to content
Home/Companies/Biotech/Pantherna Therapeutics

Pantherna Therapeutics

Biotech·Germany·Exited 2026·Held 7yr
Entry
2019
Hold
7yr
Exit
2026

Who owns Pantherna Therapeutics?

Pantherna Therapeutics was owned by High-Tech Gruenderfonds (HTGF) through HTGF III (2017 vintage) from 2019 to 2026, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-08-11

High-Tech Gruenderfonds (HTGF)
Investor
High-Tech Gruenderfonds (HTGF)
HTGF III · 2017 · VC

Key facts

HQGermany
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2026

More from HTGF III

Other portfolio companies in the same fund.

ActiTrexx
ActiTrexx
Active
BiotechGermany· 2021
Aegiq
Active
Deep TechUnited Kingdom· 2021
Altavo
Active
MedTechGermany· 2021
anybill
anybill
Active
FintechGermany· 2021
Argá Medtech
Argá Medtech
Active
MedTechSwitzerland· 2021
Avelios Medical
Avelios Medical
Active
HealthTechGermany· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Pantherna Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Pantherna Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue